JP2013513586A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513586A5
JP2013513586A5 JP2012542577A JP2012542577A JP2013513586A5 JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5 JP 2012542577 A JP2012542577 A JP 2012542577A JP 2012542577 A JP2012542577 A JP 2012542577A JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5
Authority
JP
Japan
Prior art keywords
composition according
composition
carbon atoms
active ingredient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513586A (ja
JP5663595B2 (ja
Filing date
Publication date
Priority claimed from EP09015423A external-priority patent/EP2335735A1/en
Application filed filed Critical
Publication of JP2013513586A publication Critical patent/JP2013513586A/ja
Publication of JP2013513586A5 publication Critical patent/JP2013513586A5/ja
Application granted granted Critical
Publication of JP5663595B2 publication Critical patent/JP5663595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542577A 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物 Active JP5663595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423.8 2009-12-14
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014203406A Division JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2013513586A JP2013513586A (ja) 2013-04-22
JP2013513586A5 true JP2013513586A5 (enExample) 2014-01-09
JP5663595B2 JP5663595B2 (ja) 2015-02-04

Family

ID=41731659

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012542577A Active JP5663595B2 (ja) 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Country Status (15)

Country Link
US (1) US8614178B2 (enExample)
EP (2) EP2335735A1 (enExample)
JP (5) JP5663595B2 (enExample)
KR (2) KR101652714B1 (enExample)
CN (1) CN102652022B (enExample)
AU (1) AU2010333039B2 (enExample)
BR (3) BR122020020872B1 (enExample)
CA (2) CA2941956C (enExample)
DK (1) DK2512515T3 (enExample)
ES (1) ES2449308T3 (enExample)
IN (1) IN2012DN03128A (enExample)
MX (1) MX2012006720A (enExample)
PL (1) PL2512515T3 (enExample)
PT (1) PT2512515E (enExample)
WO (1) WO2011073134A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
ES2962524T3 (es) 2011-05-25 2024-03-19 Dermaliq Therapeutics Inc Composición farmacéutica tópica a base de alcanos semifluorados
PL2806886T3 (pl) * 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
PL2895144T3 (pl) * 2012-09-12 2017-07-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów
CN113952321B (zh) 2012-09-12 2023-03-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK2708228T3 (en) 2012-09-12 2018-08-20 Novaliq Gmbh COMPOSITION FOR EYE RINSE
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
WO2014142146A1 (ja) * 2013-03-13 2014-09-18 参天製薬株式会社 マイボーム機能不全の治療剤
US10273298B2 (en) * 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
WO2015057554A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
CN110403923B (zh) * 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
CN109640900B (zh) 2016-06-23 2020-07-07 诺瓦利克有限责任公司 一种试剂盒
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019006194A2 (pt) * 2016-09-28 2019-06-18 Novaliq Gmbh composições que compreendem um ligante de ligação ao receptor de canabinóides
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
JP7032404B2 (ja) * 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
CN110650734B (zh) * 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
BR112020006072A2 (pt) 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク. mTOR阻害剤の無水組成物および使用方法
JP2022500461A (ja) 2018-09-22 2022-01-04 ノバリック ゲーエムベーハー 眼表面の損傷および乾燥の症状の治療のための眼科用組成物
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス, インコーポレーテッド 脂質バリアの修復
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
AU2020281641B2 (en) 2019-05-24 2025-09-11 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
IL322635A (en) * 2023-02-13 2025-10-01 Novaliq Gmbh Ophthalmic preparation for eye surgery in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
WO2005099718A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) * 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PT2110126E (pt) 2008-04-18 2012-02-20 Novaliq Gmbh Utilização inalativa e instilativa de alcanos semifluorados como veículos de substância activa na região intrapulmonar

Similar Documents

Publication Publication Date Title
JP2013513586A5 (enExample)
JP2013540140A5 (enExample)
JP2013518056A5 (enExample)
ES2717204T3 (es) Compuestos aminoesteroideos para una aplicación tópica local para la descolonización cutáneo-mucosa de Staphylococcus aureus
JP2019529457A5 (enExample)
JP2009544722A5 (enExample)
JP2013511496A5 (enExample)
JP2020517622A (ja) ヨウ素組成物
JP2010077141A5 (enExample)
JP6076267B2 (ja) リファキシミンの形態およびその使用
JP2009102342A5 (enExample)
TW200825094A (en) Therapeutic pyrazolyl thienopyridines
ES2641651T3 (es) Parche que contiene ropinirol y envase para el mismo
JP5805389B2 (ja) 非経口用抗菌剤
JP2013518036A5 (enExample)
JP2014516942A5 (enExample)
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
JP2013512277A5 (enExample)
HRP20151425T1 (hr) Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
JP2011527299A5 (enExample)
JP2018532698A (ja) カルボキシ置換(ヘテロ)芳香環誘導体並びにその調製方法及び使用
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
JP2015505295A5 (enExample)
EP2125872A1 (en) Basic peptides and their use as combined antibacterial-antifungine agents
JP2009040767A5 (enExample)